Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H02 vs Rituximab in DLBCL
NCT05040906Phase 3Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of H02 in diffuse large B-cell lymphoma (DLBCL), sponsored by Shandong New Time Pharmaceutical. Status: unknown.
02
Drugs
H02
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05040906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040906.